Earnings History Data for Syndax Pharmaceuticals, Inc. (SNDX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
05-11-2024	AH		SNDX	Syndax Pharmaceuticals, Inc.	1,600	-0.98	-1.13	-0.73	Syndax Pharmaceuticals GAAP EPS of -$0.98 beats by $0.05, revenue of $12.5M beats by $4.1M [11/5/2024 4:13 PM]	21.29	1.60 (8.13%)	21.00	1.31 (6.65%)	13.14 - 25.34	3,411,857	810,000	3,502
Syndax Pharmaceuticals GAAP EPS of -$0.98 beats by $0.05, revenue of $12.5M beats by $4.1M [11/5/2024 4:13 PM] Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update [2024-11-05 04:01PM] Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 [2024-11-05 09:01AM] Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting [2024-11-05 09:00AM] Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting [2024-11-05 09:00AM] Syndax agrees funding with Royalty Pharma for Niktimvo US sales [2024-11-05 04:32AM] Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo [Nov-04-24 04:15PM] Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo [Nov-04-24 04:01PM]
01-08-2024	AH		SNDX	Syndax Pharmaceuticals, Inc.	1,900	-0.80	-0.91	-0.64	Syndax Pharmaceuticals GAAP EPS of -$0.80 beats by $0.11 [8/1/2024 4:38 PM]	21.06	-0.94 (-4.27%)	22.17	0.17 (0.77%)	11.22 - 25.34	1,255,364	1,140,000	35,065
Syndax's revumenib granted FDA orphan drug designation for leukemia [8/1/2024 12:51 PM] Syndax Pharmaceuticals GAAP EPS of -$0.80 beats by $0.11 [8/1/2024 4:38 PM]
08-05-2024	PM		SNDX	Syndax Pharmaceuticals, Inc.	1,910	-0.85	-0.96	-0.59	Syndax Pharmaceuticals GAAP EPS of -$0.85 beats by $0.12 [5/8/2024 7:23 AM]	22.38	-0.80 (-3.45%)	22.38	0.0 (0.00%)	11.22 - 25.34	1,079,659	880,000	14,546
Syndax Pharmaceuticals GAAP EPS of -$0.85 beats by $0.12 [5/8/2024 7:23 AM] Syndax Pharmaceuticals Q1 2024 Earnings Preview [5/7/2024 2:09 PM]
27-02-2024	AH		SNDX	Syndax Pharmaceuticals, Inc.	1,960	-1.00	-0.99	-0.62	Syndax Pharmaceuticals GAAP EPS of -$1.00 misses by $0.04 [2/27/2024 4:15 PM]	23.86	-0.55 (-2.25%)	24.55	0.14 (0.57%)	11.22 - 25.75	929,086	1,020,000	118,244
Syndax Pharmaceuticals GAAP EPS of -$1.00 misses by $0.04 [2/27/2024 4:15 PM] FDA accepts Incyte application for graft-versus-host disease drug [2/27/2024 5:22 PM] Syndax Pharmaceuticals files for a mixed securities shelf [2/27/2024 5:52 PM]
02-11-2023	AH		SNDX	Syndax Pharmaceuticals, Inc.	978.34	-0.73	-0.80	-0.58	Syndax Pharmaceuticals GAAP EPS of -$0.73 beats by $0.07 [11/2/2023 4:45 PM]	14.84	0.06 (0.37%)	15.00	0.22 (1.49%)	11.22 - 29.86	1,362,440	1,960,000	441,732
Syndax Pharmaceuticals GAAP EPS of -$0.73 beats by $0.07 [11/2/2023 4:45 PM]
03-08-2023	AH		SNDX	Syndax Pharmaceuticals, Inc.	1,450	-0.64	-0.73	-0.62	Syndax Pharmaceuticals GAAP EPS of -$0.64 beats by $0.09 [8/3/2023 4:52 PM]	19.78	-0.57 (-2.80%)	20.35	0.0 (0.00%)	19.26 - 29.86	476,121	860,000	13,596
Syndax Pharmaceuticals GAAP EPS of -$0.64 beats by $0.09 [8/3/2023 4:52 PM]
08-05-2023	AH	4:05 PM ET (May 8)	SNDX	Syndax Pharmaceuticals, Inc.	1,380	-0.59	-0.61	-0.63	Syndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01 [5/8/2023 4:13 PM]	21.66	1.37 (6.75%)	20.29	0.0 (0.00%)	13.27 - 29.86	1,213,312	740,000	7,305
Syndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01 [5/8/2023 4:13 PM]
28-02-2023	AH	4:05 PM ET (Feb 28)	SNDX	Syndax Pharmaceuticals, Inc.	1,730	-0.62	-0.64	1.81	Syndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04 [2/28/2023 4:50 PM]	24.84	-0.51 (-2.01%)	25.35	0.0 (0.00%)	13.27 - 29.86	863,597	570,000	35,064
Syndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04 [2/28/2023 4:50 PM]
03-11-2022	AH	4:05 PM ET (Nov 3)	SNDX	Syndax Pharmaceuticals, Inc.	1,310	-0.58	-0.65	-0.40	Syndax Pharmaceuticals GAAP EPS of -$0.58 beats by $0.07; updates FY22 guidance [11/3/2022 4:49 PM]	22.33	0.0 (0.00%)	22.33	0.0 (0.00%)	13.27 - 26.51	1,015,290	730,000	6,045
Syndax Pharmaceuticals GAAP EPS of -$0.58 beats by $0.07; updates FY22 guidance [11/3/2022 4:49 PM] Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update [Nov-03-22 04:05PM] Syndax Highlights Durable Remissions For Revumenib In Acute Leukemia Patients [Nov-03-22 12:12PM] Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias [Nov-03-22 09:00AM]
08-08-2022	AH	4:05 PM ET (Aug 8)	SNDX	Syndax Pharmaceuticals, Inc.	1,170	-0.62	-0.65	-0.44	Syndax Pharmaceuticals GAAP EPS of -$0.62 [8/8/2022 4:36 PM]	24.00	-0.28 (-1.15%)	24.28	0.0 (0.00%)	13.27 - 25.71	1,744,801	620,000	17,575
Syndax Pharmaceuticals GAAP EPS of -$0.62 [8/8/2022 4:36 PM] Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update [Aug-08-22 04:05PM]
09-05-2022	AH	4:05 PM ET (May 9)	SNDX	Syndax Pharmaceuticals, Inc.	913.80	-0.63	-0.63	-0.54	Syndax Pharmaceuticals GAAP EPS of -$0.63 [5/9/2022 4:15 PM]	14.76	-0.35 (-2.32%)	14.36	-0.75 (-4.96%)	13.58 - 22.71	1,025,759	562,483	1,251
Syndax Pharmaceuticals GAAP EPS of -$0.63 [5/9/2022 4:15 PM] Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update [May-09-22 04:05PM] Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates [May-09-22 06:25PM]
01-03-2022	AH	4:05 PM ET (Mar 1)	SNDX	Syndax Pharmaceuticals, Inc.	864.02	1.81	-0.68	-0.44	Syndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92M [3/1/2022 4:21 PM]	16.07	0.01 (0.03%)	17.10	1.04 (6.48%)	13.02 - 25.68	967,561	460,000	557
Syndax appoints former Alnylam executive as new medical chief [3/1/2022 4:22 PM] Syndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92M [3/1/2022 4:21 PM] Syndax Announces Participation at Two Upcoming Investor Conferences [Feb-28-22 07:00AM] Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer [Mar-01-22 04:01PM] Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update [Mar-01-22 04:05PM]
15-11-2021	AH	4:00 PM ET (Nov 15)	SNDX	Syndax Pharmaceuticals, Inc.	857.30	-0.40	-0.62	-0.46	Syndax Pharmaceuticals EPS misses by $0.35, misses on revenue [11/15/2021 4:16 PM]	18.34	0.45 (2.52%)	17.89	0.0 (0.00%)	13.02 - 27.85	394,970	680,000	5,520
Syndax Pharmaceuticals EPS misses by $0.35, misses on revenue [11/15/2021 4:16 PM] Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update [Nov-15-21 04:05PM]
09-08-2021	AH	4:00 PM ET (Aug 9)	SNDX	Syndax Pharmaceuticals, Inc.	685.13	-0.44	-0.74	-0.42	Syndax Pharmaceuticals EPS beats by $0.28, beats on revenue [8/9/2021 4:02 PM]	15.34	0.79 (5.43%)	14.55	0.0 (0.00%)	13.02 - 27.85	284,883	310,000	6,771
Syndax Pharmaceuticals EPS beats by $0.28, beats on revenue [8/9/2021 4:02 PM] Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update [Aug-09-21 04:01PM] Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Misses Revenue Estimates [Aug-09-21 05:35PM]
11-05-2021	AH	4:05 PM ET (May 11)	SNDX	Syndax Pharmaceuticals, Inc.	773.70	-0.54	-0.63	-0.56	Syndax Pharmaceuticals EPS beats by $0.13, beats on revenue [5/11/2021 4:14 PM]	17.97	1.93 (12.03%)	16.55	0.51 (3.18%)	13.02 - 27.85	1,833,924	760,000	287
Syndax Pharmaceuticals EPS beats by $0.13, beats on revenue [5/11/2021 4:14 PM] Syndax Pharma announces new data for SNDX-5613 in trial for acute leukemias [5/11/2021 4:32 PM] Syndax Pharmaceuticals, Inc. to Host Earnings Call [May-11-21 02:30PM] Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update [May-11-21 04:01PM] Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial [May-12-21 07:51AM]
08-03-2021	AH	4:05 PM ET (Mar 8)	SNDX	Syndax Pharmaceuticals, Inc.	1,070	-0.44	-0.46	-0.44	Syndax Pharmaceuticals reports Q4 results [3/8/2021 4:12 PM]	23.70	0.40 (1.72%)	23.30	0.0 (0.00%)	6.88 - 27.85	958,928	806,826	3,094
Syndax Pharmaceuticals reports Q4 results [3/8/2021 4:12 PM] Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates [Mar-09-21 03:38AM] Syndax Pharmaceuticals: Q4 Earnings Insights [Mar-08-21 04:37PM] Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update [Mar-08-21 04:05PM] Syndax Pharmaceuticals, Inc. to Host Earnings Call [Mar-08-21 01:30PM]
02-11-2020	AH	4:05 PM ET (Nov 2)	SNDX	Syndax Pharmaceuticals, Inc.	695.43	-0.46	-0.42	-0.41	Syndax Pharmaceuticals EPS misses by $0.02, misses on revenue [11/2/2020 4:24 PM]	19.02	1.93 (11.29%)	17.09	0.0 (0.00%)	5.35 - 21.97	1,322,692	584,940	4,683

06-08-2020	AH	4:05 PM ET (Aug 6)	SNDX	Syndax Pharmaceuticals, Inc.	526.99	-0.42	-0.47	-0.47	Syndax Pharmaceuticals EPS beats by $0.05, revenue in-line [8/6/2020 4:27 PM]	16.56	1.56 (10.40%)	15.00	0.0 (0.00%)	5.35 - 21.97	462,373	202,925	3,423